the question handbill
KPV Peptide: Frequently Asked Questions
Direct answers drawn from the published literature and the audited FDA record — what is known, what is preclinical, and what has no human answer yet.
What does KPV peptide do?
KPV is the C-terminal tripeptide (residues 11-13) of alpha-MSH that retains the parent hormone's anti-inflammatory activity while lacking its pigmentary action [4]. In research models it suppresses NF-kB and MAP-kinase signaling and reduces pro-inflammatory cytokine production [1], and the effect appears largely melanocortin-receptor-independent [2].
What is KPV?
KPV stands for the tripeptide lysine-proline-valine, the C-terminal fragment of alpha-MSH studied for anti-inflammatory and gut/epithelial signaling [4]. It is not an independently circulating hormone.
Does KPV cause skin pigmentation or tanning like other melanocortins?
KPV's defining feature in the literature is anti-inflammatory action without pigmentary effect; unlike melanocortin agonists used for tanning, the C-terminal KPV fragment lacks the melanogenic activity of full alpha-MSH [4].
What is PepT1 and why does it matter for KPV?
PepT1 (SLC15A1) is an intestinal di/tripeptide transporter that carries KPV directly into epithelial cells; it is upregulated in inflamed gut tissue, which makes it a route to target KPV to the inflamed colon [1].
What are the benefits of KPV peptide?
Reported research findings include reduced colonic inflammation in mouse colitis [2], accelerated corneal re-epithelialization in rabbits (8/8 by 60 hours) [6], and downregulated inflammatory signaling across cell types [1][8]; these are preclinical findings, not demonstrated human benefits.
Can you take KPV and BPC-157 together?
No controlled study has evaluated a KPV plus BPC-157 combination in humans; the research record contains no data on co-administration of these two peptides, so no research-based combination guidance exists.
How long does it take KPV peptide to work?
There is no human timeline; in animal models effects were measured over days — for example, complete corneal re-epithelialization by 60 hours in a rabbit study [6] — but these do not translate to a human onset time.
Is KPV legal?
KPV is not an FDA-approved drug and is sold as a research chemical for laboratory use only; it is not approved as a drug or dietary supplement in any major jurisdiction [16][20]. Under the FD&C Act it could be used in 503A compounding only if it were on FDA's 503A bulks list or otherwise eligible, and KPV is currently a candidate under PCAC evaluation rather than a listed substance [16][18]. This is general information, not legal advice.
Can you get KPV from a compounding pharmacy?
Legally compounded access requires an eligible ingredient plus a licensed-prescriber evaluation and a valid, patient-specific prescription routed through a 503A pharmacy or 503B outsourcing facility, with telehealth as a possible front-end consultation channel [19]. Because KPV is currently a candidate under FDA evaluation rather than a listed bulk substance, its eligibility for routine 503A compounding is exactly the open question the July 2026 PCAC meeting is scheduled to examine; no outcome should be assumed [16][18].
What is the FDA 503A status of KPV?
KPV is a bulk drug substance "being considered for inclusion on the 503A Bulks List," individually named on the FDA Pharmacy Compounding Advisory Committee agenda for the meeting scheduled July 23-24, 2026, in both free base and acetate forms [18]. The audited FDA reference does not assign KPV a numbered 503A Category; its present-tense status is research peptide, not FDA-approved, scheduled for PCAC evaluation — a step in evaluation, not a final listing decision [16][18]. For the full picture, see KPV legal status and 503A access.